Crizotinib is a type I tyrosine kinase inhibitor that is approved for treatment of ALK-positive non-small cell lung cancer. Crizotinib is also effective against ALCL and IMTs. Development of resistance to crizotinib is not uncommon, however, with patients acquiring secondary mutations or amplifications of the ALK gene that limit the effectiveness of the drug. This pathway describes ALK mutants that are resistant to crizotinib-mediated inhibition (reviewed in Roskoski, 2013; Lin et al, 2017; Della Corte et al, 2018).
Della Corte, CM,
Di Liello, R